Pα+ Psychedelic Bulletin #217: Gilgamesh’s GM-1020 Prints Positive Topline; FDA Lifts Hold on GH Research’s 5-MeO-DMT IND; Compass Details Pivotal PTSD Trial Design; Cybin Becomes Helus

Welcome to our first Psychedelic Bulletin of 2026! It’s been a very busy start to the year, but fret not: this Bulletin will get you up to speed.Already, FDA has cleared two investigational new drug (IND) applications for psychedelic candidates, allowing two late-stage development programs to proceed in the U.S. The first sees the agency lift a clinical hold on GH Research’s inhaled 5-MeO-DMT for…

Source